
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Paris - Lasers and intense pulsed light sources (IPL) are effective for nonablative skin resurfacing of skin changes due to photoaging.